Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Lipidomic profiles, lipid trajectories and clinical biomarkers in female elite endurance athletes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Describing the fecal metabolome in cryogenically collected samples from healthy participants

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Author Correction: Characterisation and localisation of the endocannabinoid system components in the adult human testis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Pekka Peroja
  • Mette Ølgod Pedersen
  • Tuomo Mantere
  • Peter Nørgaard
  • Jenni Peltonen
  • Kirsi-Maria Haapasaari
  • Jan Böhm
  • Esa Jantunen
  • Taina Turpeenniemi-Hujanen
  • Katrin Rapakko
  • Peeter Karihtala
  • Ylermi Soini
  • Kaija Vasala
  • Outi Kuittinen
Vis graf over relationer

Diffuse large B-cell lymphoma (DLBCL) is an aggressive lymphoma with diverse outcomes. Concurrent translocation of MYC and BCL-2 and/or BCL-6, and concurrent immunohistochemical (IHC) high expression of MYC and BCL-2, have been linked to unfavorable treatment responses. TP53-mutated DLBCL has also been linked to worse outcome. Our aim was to evaluate the aforementioned issues in a cohort of 155 patients uniformly treated with R-CHOP-like therapies. We performed direct sequencing of TP53 exons 5, 6, 7 and 8 as well as fluorescence in-situ hybridization (FISH) of MYC, BCL-2 and BCL-6, and IHC of MYC, BCL-2 and BCL-6. In multivariate analysis, TP53 mutations in L3 and loop-sheet helix (LSH) associated with a risk ratio (RR) of disease-specific survival (DSS) of 8.779 (p = 0.022) and a RR of disease-free survival (DFS) of 10.498 (p = 0.011). In IHC analysis BCL-2 overexpression was associated with inferior DFS (p = 0.002) and DSS (p = 0.002). DLBCL with BCL-2 and MYC overexpression conferred inferior survival in all patients (DSS, p = 0.038 and DFS, p = 0.011) and in patients with non-GC phenotype (DSS (p = 0.013) and DFS (p = 0.010). Our results imply that in DLBCL, the location of TP53 mutations and IHC analysis of BCL-2 and MYC might have a role in the assessment of prognosis.

OriginalsprogEngelsk
TidsskriftScientific Reports
Vol/bind8
Udgave nummer1
Sider (fra-til)14814
ISSN2045-2322
DOI
StatusUdgivet - 4 okt. 2018

ID: 56605361